A recent study reveals that people who discontinue new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who stop conventional lifestyle regimens.
Findings released in a leading medical journal demonstrates that while obese people often shed a large proportion of their body weight while on the medication, the weight is regained at an average rate of 0.8 kg per month upon discontinuation.
"People using such treatments must be cognizant of the potential of fast rebound weight gain when the therapy is stopped," warns researcher Dr. Susan Jebb.
Such speed of regain means a return to original weight in about a year and a half.
Analyzing Approaches
The study, which looked at dozens of studies involving thousands of participants, compared the outcomes of the injectable medications with older methods.
The team point out that individuals who shed pounds through lifestyle changes alone usually have a less rapid creep back—around 0.1 kg a month—post-intervention.
The Reason for the Quick Regain
Doctors suggest the way of the injections explains the amplified regain.
GLP-1 drugs mimic a natural hormone called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 concentrations far above than the body's typical production might result in the system to produce less of its endogenous hormone, and may also diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement leads to appetite is unsuppressed, making excessive eating far more likely."
An Ongoing Issue?
Medical guidelines advise the jabs for individuals with obesity-related health risks, alongside recommended lifestyle changes.
Many experts contend that, due to the significant potential of relapse, the therapy should be considered ongoing.
This perspective is reinforced by drug manufacturers, who note that the results "highlight the long-term nature of excess weight," similar to managing diseases like high blood pressure.
Patient Testimonies
People who have stopped the jabs report a powerful return of appetite.
"It was like a trigger flipping and you become extremely hungry," described one woman.
The struggle is worsened if individuals have not adopted lasting lifestyle or habit changes during treatment.
Significant Adoption
Figures show that a significant number of people in the UK have used these injections in the past year, with desire remaining high.
- Adoption is more common among women than men.
- The 40s and 50s age group shows the highest level of interest.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a magic solution and lasting health benefits hinges on ongoing behavioural changes.
